Physician profile
Harsh V Gupta
NPI 1295727436
$2,600.26
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2020: $424 · 2021: $452 · 2022: $303 · 2023: $635 · 2024: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $904.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $609.57 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $470.30 | 2019-2024 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $310.23 | 2019-2024 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $248.28 | 2019-2024 | Stelara |
| Qol Medical, LLC | $176.01 | 2019-2022 | |
| Redhill Biopharma INC. | $164.83 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Gilead Sciences, INC. | $107.56 | 2019-2020 | |
| Evoke Pharma, INC. | $80.41 | 2022-2023 | Gimoti |
| Ardelyx, INC. | $55.10 | 2024 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $46.52 | 2023 | Ocaliva |
| Braintree Laboratories, INC. | $46.28 | 2020-2022 | |
| W. L. Gore & Associates, INC. | $45.36 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $43.69 | 2021-2022 | |
| Lilly USA, LLC | $35.89 | 2024 | Omvoh |
| Concordia Pharmaceuticals INC. | $30.15 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $29.31 | 2021 | |
| Daiichi Sankyo INC. | $24.51 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.43 | 2024 | Dupixent |
| Celgene Corporation | $16.48 | 2022 | |
| Allergan, INC. | $15.74 | 2019 | |
| Capsovision, INC. | $14.17 | 2023 | Capsocam Plus |
| Merck Sharp & Dohme LLC | $12.44 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$42,079.60 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harsh Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.